Recombinant Human Tie-2 His-tag Protein, CF

When Recombinant Human Tie-2 His-tag (10457-TI) is immobilized at 0.5 μg/mL (100 μL/well), Recombinant Human Angiopoietin-2 (623-AN) binds with an ED50 of 0.5-4 ng/mL.

2 μg/lane of Recombinant Human Tie-2 His-tag Protein (Catalog # 10457-TI) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Tie-2 His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human Tie-2 His-tag (Catalog # 10457-TI) is immobilized at 0.5 µg/mL (100 µL/well), Recombinant Human Angiopoietin-2 His-tag (Catalog # 623-AN) binds with an ED₅₀ of 0.5-4 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human Tie-2 protein
  Ala23-Lys745, with a C-terminal 6-His tag
• Accession #: AAA61139.1
• N-terminal Sequence: Ala23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW:

  81 kDa

  .
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 98-111 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Tie-2 His-tag Protein, CF

• angiopoietin-1 receptor
• CD202b antigen
• CD202b
• EC 2.7.10
• EC 2.7.10.1
• hTIE2
• p140 TEK
• soluble TIE2 variant 1
• soluble TIE2 variant 2
• TEK tyrosine kinase, endothelial
• TEK
• Tie2
• Tie-2
• TIE2CD202b
• Tunica interna endothelial cell kinase
• Tyrosine-protein kinase receptor TEK
• Tyrosine-protein kinase receptor TIE-2
• venous malformations, multiple cutaneous and mucosal
• VMCM
• VMCM1

Background

Tie-1/Tie (tyrosine kinase with Ig and EGF homology domains 1) and Tie-2/Tek comprise a receptor tyrosine kinase (RTK) subfamily with unique structural characteristics: two immunoglobulin-like domains flanking three epidermal growth factor (EGF)-like domains and followed by three fibronectin type III-like repeats in the extracellular region and a split tyrosine kinase domain in the cytoplasmic region. These receptors are expressed primarily on endothelial and hematopoietic progenitor cells and play critical roles in angiogenesis, vasculogenesis and hematopoiesis. Human Tie-2 cDNA encodes a 1124 amino acid (aa) precursor protein with an 18 aa putative signal peptide, a 727 aa extracellular domain (ECD) and a 354 aa cytoplasmic domain. Human Tie-2 ECD shares 90% aa identity with mouse and rat Tie-2. Two ligands, angiopoietin1 (Ang1) and angiopoietin2 (Ang2), which bind Tie-2 with high affinity, have been identified. Ang2 has been reported to act as an antagonist for Ang1. Mice engineered to over-express Ang2 or to lack Ang1 or Tie-2 display similar angiogenesis defects.

1. Partanen, J. and D.J. Dumont (1999) Curr. Top. Microbiol. Immunol. 237:159.
2. Takakura, N. et al. (1998) Immunity 9:677.
3. Procopio, W. et al. (1999) J. Biol. Chem. 274:30196.

Bioinformatics

• Uniprot:
  • AAA61139.1()